{"id":"meningococcal-a-conjugate-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":{"setId":"2dc730d5-55fd-4e98-8c8a-daa7d8f872b0","title":"MENVEO (MENINGOCOCCAL (GROUPS A, C, Y AND W-135) OLIGOSACCHARIDE DIPHTHERIA CRM197 CONJUGATE VACCINE) KIT MENVEO (MENINGOCOCCAL (GROUPS A, C, Y AND W-135) OLIGOSACCHARIDE DIPHTHERIA CRM197 CONJUGATE VACCINE) INJECTION, SOLUTION [GLAXOSMITHKLINE BIOLOGICALS SA]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The meningococcal A conjugate vaccine contains the polysaccharide capsule from Neisseria meningitidis serogroup A chemically linked to a protein carrier (conjugate). This conjugation enhances immunogenicity by promoting T-cell dependent B-cell responses, leading to robust production of protective antibodies against the meningococcal serogroup A capsule. The vaccine provides both immediate and long-lasting immunity against meningococcal disease caused by serogroup A.","oneSentence":"This vaccine stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup A by presenting the bacterial polysaccharide capsule conjugated to a protein carrier.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:00:24.300Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/Meningococcal_vaccine","title":"Meningococcal vaccine","extract":"Meningococcal vaccine refers to any vaccine used to prevent infection by Neisseria meningitidis. Different versions are effective against some or all of the following types of meningococcus: A, B, C, W-135, and Y. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin."},"indications":{"approved":[{"name":"Prevention of meningococcal disease caused by Neisseria meningitidis serogroup A"}]},"trialDetails":[{"nctId":"NCT05935176","phase":"PHASE4","title":"Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2023-09-20","conditions":"Epidemic Meningitis","enrollment":660},{"nctId":"NCT07135986","phase":"PHASE3","title":"Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-09-26","conditions":"Meningococcal Infection, Healthy Volunteers","enrollment":1602},{"nctId":"NCT04006457","phase":"PHASE3","title":"Long-Term PF-06651600 for the Treatment of Alopecia Areata","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2019-07-18","conditions":"Alopecia Areata","enrollment":1052},{"nctId":"NCT07379151","phase":"","title":"Evaluation of the Antibody Persistence Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2026-03","conditions":"Meningoccocal Disease","enrollment":450},{"nctId":"NCT07286370","phase":"PHASE2","title":"A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-02-16","conditions":"Salmonella Infections","enrollment":537},{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT06647407","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-05","conditions":"Meningococcal Immunization, Healthy Volunteers","enrollment":750},{"nctId":"NCT06128733","phase":"PHASE1, PHASE2","title":"Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-10-31","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1215},{"nctId":"NCT07320716","phase":"PHASE2","title":"Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-01-02","conditions":"Diarrhoea","enrollment":528},{"nctId":"NCT07203755","phase":"PHASE1","title":"Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine","status":"RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2025-12-19","conditions":"Diphtheria, Tetanus and Acellular Pertussis, Epidemic Meningitis, Haemophilus Influenzae Type B Infection","enrollment":260},{"nctId":"NCT06834100","phase":"PHASE3","title":"Assessment of Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE in Comparison With the Reference Drug","status":"RECRUITING","sponsor":"NPO Petrovax","startDate":"2025-02-12","conditions":"Infections, Meningococcal","enrollment":240},{"nctId":"NCT07197762","phase":"PHASE4","title":"MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-11-04","conditions":"Neisseria Meningitidis","enrollment":125},{"nctId":"NCT05073003","phase":"PHASE1","title":"A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-06","conditions":"Diarrhoea","enrollment":551},{"nctId":"NCT06284915","phase":"PHASE3","title":"Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-03-19","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":840},{"nctId":"NCT04843111","phase":"","title":"Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US)","status":"RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-03-05","conditions":"Meningococcal Infection","enrollment":50},{"nctId":"NCT07204457","phase":"PHASE2, PHASE3","title":"Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old","status":"RECRUITING","sponsor":"EyeGene Inc.","startDate":"2025-10-15","conditions":"Meningococcal Infections","enrollment":1123},{"nctId":"NCT05480800","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-09-13","conditions":"Salmonella Infections","enrollment":155},{"nctId":"NCT04825223","phase":"PHASE1","title":"Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-03-29","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":576},{"nctId":"NCT05929651","phase":"PHASE4","title":"Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-09-07","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":71},{"nctId":"NCT06228586","phase":"PHASE3","title":"Study on a MenACYW Conjugate Vaccine Administered as a Single Dose in Participants Aged 12 Months and Older in Vietnam","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-01-18","conditions":"Meningococcal Infection, Healthy Volunteers","enrollment":447},{"nctId":"NCT04368429","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-05-22","conditions":"Meningococcal Immunisation (Healthy Volunteers)","enrollment":360},{"nctId":"NCT04084769","phase":"PHASE3","title":"Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-09-03","conditions":"Meningococcal Immunisation (Healthy Volunteers)","enrollment":570},{"nctId":"NCT03890367","phase":"PHASE3","title":"Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in European Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-09-12","conditions":"Meningococcal Immunisation (Healthy Volunteers)","enrollment":707},{"nctId":"NCT04490018","phase":"PHASE3","title":"Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-03-16","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":463},{"nctId":"NCT04142242","phase":"PHASE3","title":"Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-10-04","conditions":"Meningococcal Infection (Healthy Volunteers)","enrollment":471},{"nctId":"NCT06879327","phase":"PHASE2","title":"Infant Malaria Vaccine Schedule Optimization","status":"RECRUITING","sponsor":"PATH","startDate":"2025-05-30","conditions":"Malaria Vaccines","enrollment":1200},{"nctId":"NCT06700148","phase":"PHASE3","title":"A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2024-12-14","conditions":"Meningococcal Meningitis","enrollment":840},{"nctId":"NCT06226714","phase":"PHASE3","title":"A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2024-03-01","conditions":"Meningococcal Meningitis","enrollment":840},{"nctId":"NCT04936685","phase":"PHASE3","title":"Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5- and/or 10-year Booster Doses in Children and Adolescents Vaccinated 5 or 10 Years Earlier as Toddlers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-08-23","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":209},{"nctId":"NCT06011200","phase":"PHASE3","title":"A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a 4 to 6 Year-old Population","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2023-09-16","conditions":"Epidemic Meningitis","enrollment":1000},{"nctId":"NCT04886154","phase":"PHASE1, PHASE2","title":"A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-06-14","conditions":"Infections, Meningococcal","enrollment":1440},{"nctId":"NCT03299426","phase":"PHASE3","title":"Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2018-02-21","conditions":"Typhoid","enrollment":30000},{"nctId":"NCT03295318","phase":"PHASE2","title":"Clinical Study of Meningococcal ACYWX Conjugate Vaccine, in 12-16 Month Olds","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2017-11-15","conditions":"Meningitis, Meningococcal","enrollment":375},{"nctId":"NCT05082285","phase":"PHASE2","title":"A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-11-29","conditions":"Infections, Meningococcal","enrollment":724},{"nctId":"NCT05093829","phase":"PHASE3","title":"Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate Vaccine","status":"COMPLETED","sponsor":"Emory University","startDate":"2022-03-24","conditions":"Meningitis","enrollment":1325},{"nctId":"NCT06131554","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2024-03-20","conditions":"Meningococcal Meningitis","enrollment":1480},{"nctId":"NCT03869866","phase":"PHASE3","title":"Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) in Older Adults in Turkey and Lebanon","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-04-09","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":290},{"nctId":"NCT03932682","phase":"PHASE3","title":"Efficacy Study With QIVc in Pediatric Subjects","status":"COMPLETED","sponsor":"Seqirus","startDate":"2019-05-13","conditions":"Influenza, Human","enrollment":5723},{"nctId":"NCT04318548","phase":"PHASE3","title":"Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2020-08-25","conditions":"Infections, Meningococcal","enrollment":945},{"nctId":"NCT03547271","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-12-14","conditions":"Meningococcal Infections","enrollment":1660},{"nctId":"NCT04143061","phase":"PHASE3","title":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-12-30","conditions":"Meningococcal Immunization, Healthy Volunteers","enrollment":1328},{"nctId":"NCT02942277","phase":"PHASE1","title":"Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-10-21","conditions":"Malaria","enrollment":301},{"nctId":"NCT03917654","phase":"PHASE2","title":"Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-24","conditions":"Malaria","enrollment":1301},{"nctId":"NCT03537508","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-04-25","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2627},{"nctId":"NCT03691610","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-04","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":950},{"nctId":"NCT05252715","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 Months","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2021-12-18","conditions":"Meningitis, Meningococcal","enrollment":1200},{"nctId":"NCT06314659","phase":"PHASE3","title":"Immunogenicity and Safety of Group A and C Meningococcal Polysaccharide Conjugate Vaccine in Volunteers Aged 3-5 Months","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2021-09-17","conditions":"Healthy Population","enrollment":630},{"nctId":"NCT06314685","phase":"PHASE3","title":"Immunogenicity and Safety of MCV4 in Volunteers Aged 6 Months-5 Years","status":"UNKNOWN","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2021-12-10","conditions":"Healthy Population","enrollment":2450},{"nctId":"NCT06337071","phase":"PHASE2","title":"A Study of the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Aimei Vacin BioPharm (Zhejiang) Co., Ltd.","startDate":"2024-03-20","conditions":"Meningococcal Meningitis","enrollment":1200},{"nctId":"NCT04852185","phase":"PHASE4","title":"Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana","status":"RECRUITING","sponsor":"International Vaccine Institute","startDate":"2021-08-24","conditions":"Typhoid Fever","enrollment":23000},{"nctId":"NCT04502693","phase":"PHASE3","title":"Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2020-08-14","conditions":"Infections, Meningococcal","enrollment":3657},{"nctId":"NCT06213506","phase":"PHASE2","title":"A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-01-15","conditions":"Salmonella Infections","enrollment":516},{"nctId":"NCT05739292","phase":"PHASE1","title":"Safety and Immunogenicity of Pentavalent Meningococcal Conjugate Vaccine (EuNmCV-5) in Healthy Adults Aged 19 to 55 Years Old","status":"COMPLETED","sponsor":"EuBiologics Co.,Ltd","startDate":"2023-02-28","conditions":"Infection, Meningococcal","enrollment":60},{"nctId":"NCT03673462","phase":"PHASE3","title":"Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-09-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2797},{"nctId":"NCT06165276","phase":"PHASE1","title":"A Phase I, Randomized, Modified Single-blind, Active-controlled (Infants Only), Four-stage, Step-down, Comparative, Multi-center Study","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-07-25","conditions":"Meningococcal Immunization","enrollment":285},{"nctId":"NCT03632720","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-10","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":788},{"nctId":"NCT03630705","phase":"PHASE3","title":"Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":525},{"nctId":"NCT03135834","phase":"PHASE3","title":"A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-04-24","conditions":"Meningococcal Vaccine","enrollment":1610},{"nctId":"NCT03493919","phase":"PHASE4","title":"A Sourcing Study to Collect Human Blood Samples From Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-08","conditions":"Meningitis, Meningococcal","enrollment":1021},{"nctId":"NCT01725217","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2012-11","conditions":"Meningococcal Disease","enrollment":198},{"nctId":"NCT04440163","phase":"PHASE3","title":"MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-06-17","conditions":"Meningococcal Vaccine","enrollment":2431},{"nctId":"NCT04224311","phase":"PHASE4","title":"Immunogenicity of Quadrivalent Meningococcal Conjugate Vaccine in Frequent Platelets Donors","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2020-03-12","conditions":"Preventive Immunization; Meningitis","enrollment":102},{"nctId":"NCT05298644","phase":"PHASE2, PHASE3","title":"COVID-19 Paediatric VLA2001-321 Study","status":"WITHDRAWN","sponsor":"Valneva Austria GmbH","startDate":"2022-10-01","conditions":"SARS-CoV-2 Infection","enrollment":""},{"nctId":"NCT03636906","phase":"PHASE1, PHASE2","title":"Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-04-08","conditions":"Respiratory Syncytial Virus Infections","enrollment":201},{"nctId":"NCT02509494","phase":"PHASE3","title":"Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2015-09-30","conditions":"Ebola Virus Disease","enrollment":1023},{"nctId":"NCT02324751","phase":"PHASE2","title":"Vaccines Against Salmonella Typhi","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-09","conditions":"Typhoid Fever, Enteric Fever","enrollment":112},{"nctId":"NCT02699840","phase":"","title":"Observational Safety Study of Menactra® Administered Under Standard Health Care Practice in the Russian Federation","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-02","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":100},{"nctId":"NCT02864927","phase":"PHASE4","title":"Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-07-21","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":1311},{"nctId":"NCT01890759","phase":"PHASE3","title":"Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Federation","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2013-06-25","conditions":"Meningitis, Meningococcal Infection","enrollment":300},{"nctId":"NCT03476135","phase":"PHASE3","title":"Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-02-27","conditions":"Meningococcal Infections","enrollment":91},{"nctId":"NCT02842866","phase":"PHASE3","title":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-07-15","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":907},{"nctId":"NCT02955797","phase":"PHASE3","title":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2017-02-24","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":918},{"nctId":"NCT03205371","phase":"PHASE3","title":"Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-11-07","conditions":"Meningitis, Meningococcal","enrollment":1183},{"nctId":"NCT02752906","phase":"PHASE3","title":"Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-04-15","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":810},{"nctId":"NCT02842853","phase":"PHASE3","title":"Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-07-15","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":3344},{"nctId":"NCT01732627","phase":"PHASE2","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2012-11-12","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":301},{"nctId":"NCT02199691","phase":"PHASE2","title":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2014-07-22","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":1715},{"nctId":"NCT03205358","phase":"PHASE2","title":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2015-03-31","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":188},{"nctId":"NCT01049035","phase":"PHASE2","title":"A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-12-16","conditions":"Meningitis, Meningococcal Infection","enrollment":580},{"nctId":"NCT03077438","phase":"PHASE3","title":"Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2017-02-17","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":1000},{"nctId":"NCT05095844","phase":"","title":"National Vaccine Adverse Event Reporting Survey and Etiology","status":"UNKNOWN","sponsor":"Neuroganics LLC","startDate":"2022-03-15","conditions":"COVID-19, Vaccine Adverse Reaction, Vaccine Reaction","enrollment":100000},{"nctId":"NCT03694405","phase":"PHASE4","title":"Adolescent MenACWY Booster Study","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2018-09-20","conditions":"Meningococcal Disease, Invasive","enrollment":244},{"nctId":"NCT05229536","phase":"PHASE2","title":"Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 35 Months","status":"COMPLETED","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2018-12-21","conditions":"Meningitis, Meningococcal","enrollment":720},{"nctId":"NCT04239430","phase":"","title":"Propositive (Protecting Positive People From Meningococcal Infection) Follow-up Study","status":"UNKNOWN","sponsor":"St George's, University of London","startDate":"2020-11-26","conditions":"HIV/AIDS, Meningococcal Disease","enrollment":55},{"nctId":"NCT00459316","phase":"PHASE1, PHASE2","title":"Safety of and Immune Response to a Meningitis Vaccine in HIV-Infected Children and Youth","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-06","conditions":"HIV Infections, Meningitis","enrollment":384},{"nctId":"NCT04714229","phase":"PHASE1","title":"Safety and Immunogenicity of Meningococcal Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old","status":"COMPLETED","sponsor":"EuBiologics Co.,Ltd","startDate":"2020-09-01","conditions":"Infection, Meningococcal","enrollment":60},{"nctId":"NCT01939158","phase":"PHASE3","title":"Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-10-02","conditions":"Infections, Meningococcal","enrollment":803},{"nctId":"NCT02482636","phase":"PHASE2","title":"Baby Vaccine Study (Sched3)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-08","conditions":"Infectious Diseases","enrollment":189},{"nctId":"NCT04358731","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Lot to Lot Consistency of SIIPL Meningococcal ACYWX Conjugate Vaccine and to Compare Its Safety and Immunogenicity With That of Licensed Meningococcal ACWY Vaccine Menactra® in Healthy Individuals 18-85 Years of Age","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2019-12-27","conditions":"Vaccine for Meningococcal Disease","enrollment":1640},{"nctId":"NCT04204096","phase":"PHASE3","title":"Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III)","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2020-02-04","conditions":"Typhoid","enrollment":1800},{"nctId":"NCT03964012","phase":"PHASE3","title":"Study to Assess Immunegnicity & Safety of Pentavalent Meningococcal Vaccine (NmCV-5)","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2019-08-20","conditions":"Meningococcal Meningitis","enrollment":1800},{"nctId":"NCT02810340","phase":"PHASE1","title":"Study of Meninigococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X (MCV5) in Healthy Adults","status":"COMPLETED","sponsor":"PATH","startDate":"2016-08-01","conditions":"Meningococcal Vaccines","enrollment":60},{"nctId":"NCT04875819","phase":"PHASE4","title":"Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV","status":"RECRUITING","sponsor":"Thomas Benfield","startDate":"2021-04-28","conditions":"Hiv, Meningococcal Infections, Pneumococcal Infections","enrollment":55},{"nctId":"NCT03433482","phase":"PHASE2","title":"A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-08-30","conditions":"Meningitis, Meningococcal","enrollment":1707},{"nctId":"NCT03652610","phase":"PHASE2","title":"A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-09-07","conditions":"Infections, Meningococcal","enrollment":996},{"nctId":"NCT03746665","phase":"PHASE3","title":"Maternal Immunization With MenAfriVac™","status":"UNKNOWN","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2018-12-19","conditions":"Meningitis, Meningococcal","enrollment":200},{"nctId":"NCT01144663","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-01","conditions":"Infections, Meningococcal, Meningococcal Vaccines","enrollment":2095},{"nctId":"NCT01266993","phase":"PHASE3","title":"Persistence and Booster Study of GSK Biologicals' Meningococcal Vaccine (GSK134612) in Healthy Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-01-03","conditions":"Infections, Meningococcal, Meningococcal Vaccines","enrollment":271},{"nctId":"NCT03189745","phase":"PHASE3","title":"A Study To Evaluate A Booster Dose Of Menacwy-tt Vaccine Administered 10 Years After Healthy Subjects Aged 11-17 Years Received Either Menacwy-tt Vaccine (Nimenrix(Registered)) Or Mencevax Acwy(Registered).","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-08-01","conditions":"Meningococcal ACWY Disease","enrollment":229},{"nctId":"NCT01896596","phase":"PHASE4","title":"Hepatitis B Vaccination in Infants","status":"COMPLETED","sponsor":"Public Health England","startDate":"2013-07","conditions":"Meningococcal Disease, Pneumococcal Disease, Haemophilus Influenzae Serotype b Disease","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MenAfriVac"],"phase":"marketed","status":"active","brandName":"Meningococcal A conjugate vaccine","genericName":"Meningococcal A conjugate vaccine","companyName":"PATH","companyId":"path","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup A by presenting the bacterial polysaccharide capsule conjugated to a protein carrier. Used for Prevention of meningococcal disease caused by Neisseria meningitidis serogroup A.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}